Coronavirus vaccine update: CureVac's vaccine triggers immune response; AstraZeneca's real-time review starts in UK
German biotech firm CureVac has revealed its vaccine candidate has triggered an immune response during its phase 1 trials. The UK government has also started the process of the rolling review of AstraZeneca's candidate ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers COVID-19 vaccine likely to be available in early 2021: K'taka health minister
Speaking to reporters after a meeting with AstraZeneca Managing Director Gagan Singh Bedi, he said the first phase of trials of the vaccine were encouraging Oxford Covid-19 vaccine produces immune response among elderly: AstraZeneca
The Financial Times reported that the vaccine, being developed by Oxford and AstraZeneca, triggers protective antibodies and T-cells in older age groups. It cited two people familiar with the finding
COVID-19: Second phase of Oxford vaccine trials completed in Mumbai, BMC set to start third phase
Pune-based Serum Institute of India has partnered with AstraZeneca for manufacturing the Oxford COVID-19 vaccine candidate. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday, November 5, 2020
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2020 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Thursday, November 5, 2020 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2020 We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from September 16, 2020 to November 7, 2020 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. Coronavirus vaccine: Volunteer in AstraZeneca trials in Brazil dies; reportedly did not receive vaccine
AstraZeneca vaccine trials: An AstraZeneca spokesperson, while declining to comment on the volunteer's death, said that there were no concerns that would lead the trials to be paused Coronavirus vaccine update: UK plans to infect volunteers with COVID-19; AstraZeneca US trials to resume
Coronavirus vaccine news: Britain will help fund trials using a manufactured COVID-19 virus to deliberately infect young healthy volunteers with the hope of accelerating the development of vaccines against it AstraZeneca Pharma India Ltd - 506820 - Shareholding for the Period Ended September 30, 2020
AstraZeneca Pharma India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here Donald Trump may secure AstraZeneca's Covid-19 vaccine before UK does
This counters hopes that the Oxford vaccine would be available in the UK as soon as it cleared all trials